Roth Capital analyst Roth Capital maintained a Hold rating on Lemaitre Vascular (LMAT – Research Report) yesterday and set a price target of $58.00. The company’s shares closed last Tuesday at $55.95.
Currently, the analyst consensus on Lemaitre Vascular is a Moderate Buy with an average price target of $61.75, a 12.8% upside from current levels. In a report issued on July 30, Stifel Nicolaus also maintained a Hold rating on the stock with a $60.00 price target.
Lemaitre Vascular’s market cap is currently $1.21B and has a P/E ratio of 39.10. The company has a Price to Book ratio of 18.44.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LMAT in relation to earlier this year. Most recently, in June 2021, George W. Lemaitre, the Chairman & CEO of LMAT bought 31,733 shares for a total of $458,367.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.